CD146 最早被发现于黑色素瘤、前列腺癌和乳腺癌细胞上，后研究发现CD146存在膜型和可溶性两种 形式，其中膜形式的 CD146 广泛分布于血管内皮细胞、平滑肌细胞、淋巴细胞等组织细胞上，起到血 管发生发展、细胞黏附迁移、免疫应答及细胞分化等作用。膜型 CD146 的胞外区经过金属蛋白酶切割 等生理过程，从细胞表面脱落进入组织液中，形成可溶性 CD146（soluble CD146，sCD146）。sCD146 与膜型CD146 相比，缺失胞内区域和跨膜区域，其余结构与膜型 CD146 相同。研究表明，在多发性硬 化症、视神经脊髓炎等中枢神经系统免疫性炎性脱髓鞘病人中，血脑屏障内皮细胞中的膜型CD146表达 升高，同时由于金属蛋白酶的表达增加等因素，脑脊液中sCD146 的浓度明显升高。在中枢神经系统免 疫性炎性脱髓鞘病人的脑脊液中，sCD146 的浓度与多种炎症因子（如TNFα、IFNγ、IL-2、IL-17A 等）的浓度呈正相关，且相较于其他与疾病进程相关的分子标志物，如金属蛋白酶（MMP2、 MMP9）、可溶性粘附因子（sICAM、sVCAM）、炎症因子（LI-1β、IL-17A、IL-10、IFN- ...

Core Insights - Company Aihuilong (688575.SH) has received a medical device registration certificate for its soluble CD146 detection kit, marking a significant milestone in its product development [1] Group 1: Product Development - The product, named soluble CD146 detection kit (chemiluminescence method), has been registered with the Guangdong Provincial Drug Administration under registration number 20252401494 [1] - This diagnostic product is the first test kit globally to utilize the innovative biomarker soluble CD146, which was discovered by Academician Yan Xiyun from the Institute of Biophysics, Chinese Academy of Sciences [3] Group 2: Research and Collaboration - Aihuilong is collaborating with top medical institutions, including Peking University First Hospital, Beijing Xuanwu Hospital, and Peking University Third Hospital, to explore the potential applications of soluble CD146 [3] - The approval of this diagnostic reagent is a result of years of research and development in partnership with Academician Yan's team, showcasing the successful transformation of academic research into practical medical solutions [3] Group 3: Market Position and Product Line - With this new registration, Aihuilong has now obtained a total of 173 domestic medical device registration certificates for chemiluminescent reagents, contributing to a total of 250 such registrations [3] - The new product enhances Aihuilong's portfolio in the field of neurological disease diagnostics, expanding its automated chemiluminescence product line [3]

Core Viewpoint - The enthusiasm for applying for green factory certification has significantly increased among enterprises, driven by policy support and market demand, with a total of 1,382 new national-level green factories expected in 2024, bringing the cumulative total to 6,430 [1][5]. Summary by Sections Application Requirements Update - The application process for green factory certification has been simplified, with the removal of third-party evaluation reports, allowing companies to self-report through an online platform [2][3]. - The new evaluation criteria have been streamlined, reducing the number of secondary indicators from 92 to 14, focusing on five primary indicators: energy decarbonization, resource efficiency, clean production, product greenness, and land intensiveness [2][3]. Increased Standards for Certification - The evaluation now emphasizes quantitative assessments, with 11 out of 14 secondary indicators being quantitative, requiring companies to meet industry benchmarks for energy consumption and carbon emissions [3]. - The weight of the "energy decarbonization" criterion is set at 30%, necessitating detailed calculations of energy consumption and carbon emissions [3]. Corporate Engagement in Green Factory Applications - The number of applications for green factory certification has surged due to local government incentives, with financial rewards ranging from 200,000 to 1,000,000 yuan for successful applicants [5]. - Companies are increasingly motivated to pursue green factory status to comply with stricter environmental regulations and to enhance their market competitiveness [5][6]. Technological Innovation and Digital Management - Enterprises are leveraging technological innovations and digital management to facilitate their green transformation, focusing on energy efficiency and carbon reduction [7][8]. - The integration of digital technologies, such as IoT sensors and data analytics, is becoming crucial for real-time monitoring and optimization of energy consumption [8][9]. Recommendations for Companies - Companies are advised to maintain comprehensive records of their energy consumption and emissions data to support their green factory applications [9]. - It is recommended that enterprises prepare for certification by implementing systematic management practices and aligning with industry standards for sustainability reporting [9].

Core Points - The Shanghai Composite Index is currently at 3996.35 points, above the annual line, with a decline of 0.16% and a total trading volume of 1,602.079 billion yuan [1] - A total of 32 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The stocks with the highest deviation rates include Mannesmann (5.00%), Yahui Long (4.97%), and Xuan Ya International (4.31%) [1] - Mannesmann's stock price increased by 7.00% with a turnover rate of 18.49% [1] - Yahui Long's stock price rose by 6.78% with a turnover rate of 3.82% [1] - Xuan Ya International's stock price increased by 6.82% with a turnover rate of 17.96% [1] Other Notable Stocks - ST Nuotai and Digital People also showed positive performance with increases of 3.64% and 3.22%, respectively [1] - The stocks with smaller deviation rates that just crossed the annual line include Jianhui Information, Sinopec, and Xianggang Technology [1] Trading Volume - The total trading volume of A-shares today reached 1,602.079 billion yuan, indicating active market participation [1]

Group 1 - The core point of the news is that Aihuilong's stock price increased by 5.21% to 16.15 CNY per share, with a trading volume of 1.59 billion CNY and a turnover rate of 1.77%, resulting in a total market capitalization of 9.212 billion CNY [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay methods [1] - The company's revenue composition includes self-produced reagents (non-COVID products) at 58.57%, self-produced consumables (non-COVID products) at 12.60%, self-produced instruments (non-COVID products) at 11.92%, and various agency sales [1] Group 2 - Among Aihuilong's top ten circulating shareholders, Huabao Fund holds a significant position, having reduced its holdings by 1.7669 million shares in the third quarter, now owning 9.6516 million shares, which is 1.69% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) has a total scale of 26.404 billion CNY and has achieved a year-to-date return of 11.75% [2] - The fund manager, Hu Jie, has a tenure of 13 years and 31 days, with the fund's total asset scale reaching 100.204 billion CNY [3]

Core Viewpoint - Recently, the company received a medical device registration certificate issued by the National Medical Products Administration for its product, the Human Chorionic Gonadotropin and β Subunit Determination Kit (Chemiluminescence Method) [2] Company Summary - The product is designed for the determination of human chorionic gonadotropin and its β subunit, indicating its application in medical diagnostics [2] - The approval from the regulatory authority signifies a potential expansion in the company's product offerings and market reach [2] Industry Summary - The announcement reflects ongoing developments in the medical device sector, particularly in diagnostic tools [2] - Regulatory approvals are crucial for companies in the healthcare industry, as they can lead to increased market opportunities and revenue growth [2]

证券代码：688575 证券简称：亚辉龙 公告编号：2025-058 深圳市亚辉龙生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 人绒毛膜促性腺激素（HCG）是由胎盘滋养层细胞分泌的一种异二聚体糖蛋白，包 含 92 个氨基酸组成的α亚基和 145 个氨基酸组成的β亚基，分子量为 37 kDa。其α亚 基与促甲状腺激素（TSH），促黄体生成素（LH），促卵泡激素（FSH）的α亚基相同， 而β亚基各不相同，赋予激素生物学和免疫学特异性。HCG 在产生、分泌和代谢过程中， 会发生断裂、离解等变化，而以多种不同的形式存在，血液中形式包括完整 HCG、缺口 HCG、完整游离α亚基、大分子游离α亚基、完整游离β亚基、缺口游离β亚基、β亚 基羧基末端丢失的 HCG，在尿中则存在β核心片段。正常妊娠时，完整 HCG 在受精后 7 天左右可在母体检测到，其后呈指数增长，至妊娠 9～11 周达到高峰，妊娠 3 个月后显 著降低，且异位妊娠比宫内孕完整 HCG 明显降低，HCG 检测临床上用于异位妊娠、早孕 的辅助诊断。HCG 的异常升高还常见于妊娠滋养细胞疾病、睾丸癌、膀胱癌等恶性肿瘤。 绒毛膜癌是一种恶性滋养层细胞 ...

Core Insights - The company, Aihuilong (688575.SH), has received a medical device registration certificate from the National Medical Products Administration for its Human Chorionic Gonadotropin (HCG) and β Subunit Assay Kit (Chemiluminescence Method) [1][3] - The product is intended for in vitro quantitative measurement of HCG and its β subunit in human serum and/or plasma, primarily for dynamic monitoring of malignant tumor patients to assist in assessing disease progression or treatment efficacy [1][2] Product Details - HCG is a glycoprotein hormone secreted by trophoblast cells of the placenta, consisting of an α subunit and a β subunit, with a molecular weight of 37 kDa [2] - The hormone exists in various forms in the blood, including intact HCG, free α subunit, and free β subunit, and is used clinically for diagnosing ectopic pregnancy and early pregnancy [2] - Abnormal elevation of HCG is often associated with malignant tumors such as testicular cancer and bladder cancer, with β-HCG being a valuable marker for monitoring trophoblastic diseases [2] Company Developments - The company has obtained a total of 172 domestic medical device registration certificates for chemiluminescence reagents, contributing to a total of 249 registrations [3] - The recent registration enhances the company's automated chemiluminescence product line and expands its testing portfolio in reproductive hormones and tumor markers [3]

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration for a new product, enhancing its product line in the field of reproductive hormones and tumor markers [1] Product Development - The newly approved product is a human chorionic gonadotropin and β-subunit assay kit (chemiluminescence method) for the quantitative determination of human chorionic gonadotropin and β-subunit levels in human serum and/or plasma [1] - This product enriches the company's fully automated chemiluminescence product line [1] Market Impact - The sales performance of the new product will be influenced by market conditions, making it difficult for the company to predict its impact on future performance [1]

Core Viewpoint - The company, Aihuilong (688575.SH), has received a medical device registration certificate from the National Medical Products Administration for its product, which is a kit for the quantitative determination of human chorionic gonadotropin and its beta subunit in serum or plasma [1] Group 1 - The product is intended for in vitro quantitative measurement of human chorionic gonadotropin and its beta subunit levels in human serum and/or plasma [1] - It is primarily used for dynamic monitoring of malignant tumor patients to assist in assessing disease progression or treatment effectiveness [1] - The product is not intended for early diagnosis or confirmation of malignant tumors and is not used for tumor screening in the general population [1]